Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
30
|
pubmed:dateCreated |
1988-11-21
|
pubmed:abstractText |
By use of an enzyme-linked immunosorbent assay, we have found that phorbol 12-myristate 13-acetate (PMA) causes an approximately 10-fold increase in the level of type-1 plasminogen activator inhibitor (PAI-1) accumulated in conditioned medium of the human rhabdomyosarcoma cell line. Half-maximal stimulation occurred at approximately equal to 15 nM PMA. The effect was only observed with phorbol esters that are tumor promoting. Maximal levels of secreted PAI-1 were observed 24 h after PMA addition. The increase in secreted PAI-1 was preceded by a transient approximately 10-fold increase in intracellular PAI-1 content, maximal at 8 h after PMA addition. There was a 20-fold increase in the cellular level of two 2.3- and 3.4-kilobase PAI-1 mRNAs and a more than 5-fold increase in the PAI-1 gene transcription rate. The protein synthesis inhibitor cycloheximide (10 micrograms/ml) also increased the level of PAI-1 mRNA, and when both cycloheximide and PMA were used, an additive effect was observed. Cycloheximide changed the ratio between the two PAI-1 mRNAs in favor of the 3.4-kilobase species. Overall, the data show that transcriptional activation of the PAI-1 gene forms part of the pleiotropic responses to tumor-promoting phorbol esters.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cycloheximide,
http://linkedlifedata.com/resource/pubmed/chemical/Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Phorbol Esters,
http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen Inactivators,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Tetradecanoylphorbol Acetate,
http://linkedlifedata.com/resource/pubmed/chemical/phorbol-12,13-didecanoate
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0021-9258
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
25
|
pubmed:volume |
263
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
15688-93
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3262618-Blotting, Northern,
pubmed-meshheading:3262618-Cell Line,
pubmed-meshheading:3262618-Cycloheximide,
pubmed-meshheading:3262618-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:3262618-Glycoproteins,
pubmed-meshheading:3262618-Humans,
pubmed-meshheading:3262618-Phorbol Esters,
pubmed-meshheading:3262618-Plasminogen Inactivators,
pubmed-meshheading:3262618-RNA, Messenger,
pubmed-meshheading:3262618-Rhabdomyosarcoma,
pubmed-meshheading:3262618-Tetradecanoylphorbol Acetate,
pubmed-meshheading:3262618-Transcription, Genetic
|
pubmed:year |
1988
|
pubmed:articleTitle |
Plasminogen activator inhibitor type-1 protein, mRNA and gene transcription are increased by phorbol esters in human rhabdomyosarcoma cells.
|
pubmed:affiliation |
Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|